LENZ Therapeutics Inc (LENZ NASDAQ) stock market data APIs
$3.4469
0.17(4.9%)
as of November 4, 2026
Try our APIs with
free plan!
LENZ Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Prev. Close
3.4469
Open
3.6209
High
3.7299
Low
3.3699
52 wk Range
2.8-32.13
Market Cap
109 M
Shares Outstanding
31 420 K
Revenue
12 359 K
EPS
-0.99
Beta
1.809
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with LENZ Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get LENZ Therapeutics Inc data using free add-ons & libraries
Get LENZ Therapeutics Inc Fundamental Data
LENZ Therapeutics Inc Fundamental data includes:
- Net Revenue: 12 359 K
- EBITDA: -149 251 008
- Earnings Per Share: -4
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-10-28
- EPS/Forecast: -0.97
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
LENZ Therapeutics Inc News
New
LENZ Therapeutics, Inc. (LENZ) Reports Q3 Loss, Misses Revenue Estimates
LENZ Therapeutics, Inc. (LENZ) came out with a quarterly loss of $0.99 per share versus the Zacks Consensus Estimate of a loss of $0.97. This compares to a loss of $0.59 per share a year ago. These fi...
Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
The market expects Regeneron (REGN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended September 2026. This widely-known consensus outloo...
Lenz drops as BofA downgrades on a slower VIZZ launch
[Republican Politics and Wall Street] Douglas Rissing Shares of Lenz Therapeutics (LENZ [https://seekingalpha.com/symbol/LENZ]) slipped for the third consecutive session on Thursday after Bank of Ame...
LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary
LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you ...
Get LENZ Therapeutics Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.